Market Exclusive

Edge Therapeutics, Inc. (NASDAQ:EDGE) Files An 8-K Results of Operations and Financial Condition

Edge Therapeutics, Inc. (NASDAQ:EDGE) Files An 8-K Results of Operations and Financial ConditionItem 2.02

Results of Operations and Financial Condition

On August 1, 2017, Edge Therapeutics, Inc. issued a press release announcing its financial results for the three months ended June 30, 2017. A copy of that press release and the financial schedules attached thereto is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2 of Form 8-K, the information set forth in this Current Report on Form 8-K is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The information in this Item 2.02, as well as Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act regardless of any general incorporation language in such filing.

Item 9.01.

Financial Statements and Exhibits

Description

99.1

Press release dated August 1, 2017 announcing financial results for the three months ended June 30, 2017.

Edge Therapeutics, Inc. ExhibitEX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1     Edge Therapeutics Reports Second Quarter 2017 Financial Results and Continued Operational Progress BERKELEY HEIGHTS,…To view the full exhibit click here
About Edge Therapeutics, Inc. (NASDAQ:EDGE)
Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize, hospital-based therapies capable of transforming treatment paradigms in the management of life-threatening neurological and other conditions. Edge is evaluating EG-1962, its lead product candidate, in the Phase 3 NEWTON 2 study in adult patients with aneurysmal subarachnoid hemorrhage (aSAH). This study will evaluate EG-1962’s ability to improve patient outcomes versus standard of care oral nimodipine after an aSAH resulting from a ruptured brain aneurysm. Edge’s product candidates utilize Precisa, a platform with a approach that seeks to enable targeted and sustained drug exposure at the site of injury, while potentially avoiding off-target side effects associated with systemic delivery. Edge is also using its Precisa development platform to develop additional product candidates targeting other acute, serious conditions where limited or no current therapies exist.

Exit mobile version